Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy.
Bolon B, Stolina M, King C, Middleton S, Gasser J, Zack D, Feige U. Bolon B, et al. Among authors: feige u. J Biomed Biotechnol. 2011;2011:569068. doi: 10.1155/2011/569068. Epub 2010 Dec 28. J Biomed Biotechnol. 2011. PMID: 21253435 Free PMC article. Review.
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P. Stolina M, et al. Among authors: feige u. Arthritis Res Ther. 2009;11(6):R187. doi: 10.1186/ar2879. Epub 2009 Dec 11. Arthritis Res Ther. 2009. PMID: 20003323 Free PMC article.
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis.
Stolina M, Bolon B, Dwyer D, Middleton S, Duryea D, Kostenuik PJ, Feige U, Zack DJ. Stolina M, et al. Among authors: feige u. Biomarkers. 2008 Nov;13(7):692-712. doi: 10.1080/13547500802651911. Biomarkers. 2008. PMID: 19096963
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis.
Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D, Zhu L, Rohner A, Pretorius J, Kostenuik P, Feige U, Zack D. Stolina M, et al. J Clin Immunol. 2009 Mar;29(2):158-74. doi: 10.1007/s10875-008-9238-8. Epub 2008 Aug 26. J Clin Immunol. 2009. PMID: 18726678
Analysis of the kinetics of osteoclastogenesis in arthritic rats.
Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, Zhu L, Feige U, Zack DJ. Schett G, et al. Arthritis Rheum. 2005 Oct;52(10):3192-201. doi: 10.1002/art.21343. Arthritis Rheum. 2005. PMID: 16200623
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis.
Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, Middleton S, Brown H, Pretorius J, Schett G, Bolon B, Feige U, Zack D, Kostenuik PJ. Stolina M, et al. J Bone Miner Res. 2005 Oct;20(10):1756-65. doi: 10.1359/JBMR.050601. Epub 2005 Jun 6. J Bone Miner Res. 2005. PMID: 16160733
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models.
Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, Pretorius J, Zack DJ, Kostenuik P, Feige U. Schett G, et al. Arthritis Rheum. 2005 May;52(5):1604-11. doi: 10.1002/art.21021. Arthritis Rheum. 2005. PMID: 15880601
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases.
Edwards CK 3rd, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Ellen Cosenza M, Feige U, Kohno T. Edwards CK 3rd, et al. Adv Drug Deliv Rev. 2003 Sep 26;55(10):1315-36. doi: 10.1016/s0169-409x(03)00112-1. Adv Drug Deliv Rev. 2003. PMID: 14499710 Review.
73 results
Jump to page
Feedback